



POSTER PRESENTATION

Open Access

# Targeting HIV Gag p24 to DCIR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates

A Flamar<sup>1\*</sup>, R Le Grand<sup>2</sup>, V Contreras<sup>2</sup>, S Zurawski<sup>1</sup>, N Dereuddre-Bosquet<sup>2</sup>, I Mangeot<sup>2</sup>, F Martinon<sup>2</sup>, S Oh<sup>1</sup>, J Banchereau<sup>1</sup>, G Zurawski<sup>1</sup>, Y Levy<sup>3</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

Targeting Dendritic Cells (DCs) with anti-DC receptor antibody-antigen fusion proteins is a novel approach in vaccine development for inducing potent humoral and cellular immune responses.

## Methods

We engineered an anti-human DCIR recombinant antibody cross-reacting with the cynomolgus macaque receptor fused via the heavy chain C-terminus to HIV-1 Gagp24 protein (anti-DCIR.Gagp24). HIV patient PBMC cultures were incubated with anti-DCIR and control hIgG4.Gagp24 fusion proteins. After 10 days, the total T cells were challenged with HIV Gagp24 peptide pools, and then antigen-specific cytokine production was detected using intracellular staining. Macaques were also immunized i.d. 3 times with anti-DCIR.Gagp24 or control hIgG4.Gagp24 with or without polyI:C. Gagp24-specific IgG titers from serum were measured by ELISA and the magnitude of the antigen-specific IFN $\gamma$  responses was assessed by ELISPOT.

## Results

In vitro, low doses of anti-DCIR Gagp24 prototype vaccine, but not the control hIgG4.Gagp24, expand of Gagp24-specific T cells. These in vitro-expanded antigen-specific T cells were multifunctional, simultaneously producing multiple cytokines (IFN $\gamma$ , TNF $\alpha$  and MIP-1 $\beta$ ). In vivo, in non-adjuvanted naïve animals, serum anti-Gagp24 antibodies were detectable 2 weeks after priming and titers were substantially increased after the 1st and

the 2nd boost with anti-DCIR.Gagp24 and were durable, while in the control hIgG4.Gagp24 group the responses were minimal. Poly I:C increased the magnitude of the responses in the anti-DCIR.Gagp24 and hIgG4.Gagp24 groups to a similar level in both groups. T cell responses induced by anti-DCIR Gagp24 could be enhanced after priming with a recombinant modified vaccinia virus Ankara (MVA) encoding HIV Gag/Pol/Nef. Boosting with anti-DCIR.Gagp24 plus poly I:C generated high titers of anti-Gagp24 antibody titers and strongly enhanced IFN $\gamma$ -producing T cells following priming with MVA HIV Gag/Pol/Nef.

## Conclusion

Our results demonstrate that heterologous prime-boost immunization with vectors and DC-targeting protein-based vaccines is a promising vaccination approach to optimize humoral and cellular immunity for therapeutic and preventive applications against AIDS.

## Author details

<sup>1</sup>Baylor Institute for Immunology Research, Dallas, TX, USA. <sup>2</sup>CEA, Fontenay-aux-Roses, France. <sup>3</sup>INSERM U955, Faculté de Médecine de Créteil, Créteil, France.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P358

**Cite this article as:** Flamar *et al.*: Targeting HIV Gag p24 to DCIR on dendritic cells induces T cell and potent and long-lasting antibody responses in non-human primates. *Retrovirology* 2012 **9**(Suppl 2):P358.

<sup>1</sup>Baylor Institute for Immunology Research, Dallas, TX, USA  
Full list of author information is available at the end of the article